Reversible hyporegenerative anemia during natalizumab treatment

Mult Scler. 2015 Feb;21(2):257-8. doi: 10.1177/1352458514546516. Epub 2014 Sep 3.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Anemia / chemically induced*
  • Female
  • Humans
  • Immunologic Factors / adverse effects*
  • Male
  • Multiple Sclerosis, Relapsing-Remitting / drug therapy*
  • Natalizumab / adverse effects*

Substances

  • Immunologic Factors
  • Natalizumab